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ABSTRACT Silver-Russell syndrome (SRS) is a heterogeneous disorder associated with intrauterine and postnatal
growth retardation, skeletal asymmetry and facial dysmorphisms. In 7-10% of patients maternal uniparental disomy
for chromosome 7 can be observed, nearly 50% of patients carry an epimutation resulting in hypomethylation of the
imprinting center region 1 (ICR1) in 11p15. This leaves 40% of patients with unknown genetic aetiology. Based on
the observation that the CTCF homologue BORIS is involved in imprinted gene expression and that it binds to
methylated alleles we assumed that loss-of-function mutations in BORIS might have similar functional consequences
as an ICR1 hypomethylation. On the other hand, there is evidence that BORIS mutations may disturb the methylation
process and therefore cause hypomethylation in the ICR1. In our study we searched for BORIS gene mutations in a
mixed cohort of SRS patients with and without 11p15 hypomethylation to determine whether this gene is involved
in SRS aetiology. Mutation analyses revealed eight genomic variants but pathogenic mutations were not observed.
Thus we conclude that alterations of the BORIS gene are probably not associated with SRS.
INTRODUCTION
Silver Russell syndrome (SRS) (OMIM#
180860) was firstly described in 1953 by Silver
and in 1954 by Russell (Silver et al. 1953; Russell
1954). The disorder is clinically variable but the
major features are intrauterine and postnatal
growth retardation, a characteristic triangular
face with a prominent forehead, skeletal asymme-
try and feeding difficulties. Maternal uniparental
disomy of chromosome 7 (UPD(7)mat) is a
frequent finding in SRS accounting for nearly
10% of persons  (for review: Eggermann et al.
2008a). Additionally, structural chromosomal
aberrations have been reported for several times
in SRS affecting chromosomes 7 and 11, among
them duplications of 7p11.2p-p13 and 11p15
(Abu-Amero et al. 2008).
The finding of chromosomal disturbances
and altered imprinting in 11p15 in children with
SRS phenotype focused the research for the
etiology of SRS on this region (for review:
Eggermann et al. 2008a). The 11p15 region
contains two clusters of imprinted genes each of
which is regulated by its own imprinting control
region (ICR). The H19 and IGF2 (insuline growth
factor-2) genes are controlled by the ICR1 while
in the ICR2 the expression of KCNQ1 and
CDKN1C is regulated by the centromeric
KvDMR1 domain (for review: Gicquel et al. 2005).
In SRS, epimutations in 11p15 are restricted to
the ICR1, hypomethylation in this region can be
detected in approximately 50% of persons .
Numerous studies on epigenetic regulation
mechanisms have identified many of the enzymes
and structural proteins that interact to constitute
chromatin organization and regulate gene
expression. Epigenetic regulation includes post
translational histone modification by silencing
complexes, DNA methylation, and the formation
of epigenetic chromatin by RNAs and RNA
interference (Grewal and Moazed 2003; Robertson
2005). In particular DNA methylation is a potent
mechanism for silencing gene expression and
maintaining genome stability. A central role in
gene expression in the ICR1 is mediated by the
CTCF  protein (CCCTC-binding factor (zinc finger
protein) whose binding silences IGF2 expression
but enhances H19 realization (Hore et al. 2008).
In 2002, Loukinov et al. reported that the CTCF
protein has a family member, a sibling protein
that shares the same 11ZF domain with CTCF
but acts differently from CTCF. CTCF and his
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paralogue BORIS (Brother Of Regulator of
Imprinted Sites) are DNA-binding epigenetic
regulators of gene expression by influencing the
nuclear architecture and transcriptional control.
The two proteins show similar DNA-binding
capabilities although they have probably oppo-
site regulatory effects on gene activities. They
are responsible for a parent-of-origin specific
monoallelic gene expression. The ICR1 in 11p15
is methylated during spermatogenesis, specifi-
cally marking the paternally derived chromosome.
CTCF binds to the unmethylated maternal ICR1
and protects this region from methylation.
Additionally, CTCF blocks IGF2 access to its
enhancer and finally stimulates H19 expression
(Klenova et al. 2002; Loukinov et al. 2002; Hore
et al. 2008). CTCF also negatively regulates BORIS
expression (Renaud et al. 2007). In addition,
BORIS appears to be essential for the esta-
blishment of differential methylation of the ICR1
(for review: Hore et al., 2008).  Therefore we
decided to screen SRS patients with ICR1 hypo-
methylation. We hypothesized that mutations in
BORIS may lead to a disturbed methylation on
the paternal chromosome 11 and thus result in
ICR1 hypomethylation during spermatogenesis.
Nevertheless, a recent study has shown
another function of BORIS: Nguyen et al.  (2008)
proposed that BORIS binding activity is largely
independent from the methylation status of its
target sequence. Furthermore, BORIS should
preferentially bind to methylated DNA-binding
sites because it is prevented from binding to
unmethylated target sites by CTCF (Nguyen et al.
2008). We therefore assumed that mutations in
BORIS might prevent its binding to the methylated
ICR1, the functional result should be similar to
that ICR1 hypomethylation which allows CTCF to
bind and therefore inhibits BORIS from binding
and working properly. However, Bernier- Latmani
et al. (2009  ) did not find  evidence  for  mutations
in BORIS gene in 36 SRS patients  and with ICR1
hypomethylation. Therefore we decided to
analyze SRS patient without an ICR1 hypo-
methylation. It is worthy to study as  there is
functional evidence for its central role in
establishment and regulation of the ICR1 in 11p15.
MATERIAL  AND  METHODS
Study Population
The study population consisted of 20  with
the clinical diagnosis of SRS, 10 of these patients
carried a hypomethylation in 11p15, 10 were
idiopathic. Chromosomal aberrations, UPD(7)mat
as well as endocrinological abnormalities were
excluded before. Hypomethylation in the ICR1
on 11p15 was confirmed/excluded by MS-MLPA
(Eggermann et al. 2008b). The diagnosis of SRS
was based on at least three of the following
criteria: intrauterine and postnatal growth
retardation, a triangular face, relative macro-
cephaly and skeletal asymmetry. The control
cohort consisted of 140 healthy German controls.
The study was approved by the ethical
committee of the University Hospital Aachen.
DNA Analysis
 Genomic DNA was extracted from peripheral
blood lymphocytes by standard techniques. All
samples were preamplified by whole genome
amplification (WGA) using the WGA kit provided
by SigmaAldrich (Saint Louis/USA) to increase
the amount of DNA.
The BORIS gene consists of ~28 kb and 11
exons. The genomic DNA sequence of the BORIS
gene was taken from AceView (http://
www.ncbi.nig.gov). Information on primers and PCR
conditions can be obtained from Table 1. PCR was
performed according to standard protocols in a 25
µl volume using recombinant Taq Polymerase
(Invitrogen GmbH, Karlsruhe/Germany). Fragment
sizes were between 120-550 bp. Due to its size exon
11 was divided into three overlapping fragments.
PCR products were directly sequenced using the
Big Dye Terminator Cycle Sequencing System (ABI,
Weiterstadt/Germany). For rapid genotyping of 140
control DNA samples for the variant p.V329I in exon
5 of the BORIS gene, we established a pyrose-
quencing approach using the following primers:
BORIS-Pyro-Forward 5´AAC TAT GTG ATT TTA
CAG GAA CCA GGC CCT AC 3´, Reverse 5´CAT
GAG TAT GTT TAT AGC GCC TGT GTC GG 3  ´and
for sequencing analyze BORIS-Pyro-S 5´TGT CAC
CAG TGG AGA A 3 .´
RESULTS  AND  DISCUSSION
In our total cohort of 10 SRS patients with a
11p15 hypomethylation and 10 patients without
known (epi)genetic mutation we detected 8
genomic variants. Five of them have previously
been reported (Table 2). We identified three so
far unknown variants in exons 5 and 9 and in the
3´- untranslated region of exon 11, respectively.
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In exon 5 we found heterozygosity for a G>A
transition at nucleotide position g.6267 leading
to a change from Val to Ile (p.V329I) in one SRS
patient with ICR1 hypomethylation. By screening
140 healthy controls we failed to find the same
substitution but sequencing of the patients´
healthy mother revealed heterozygosity for the
same variant. Based on this finding and the fact
that this amino acid residue is not evolutionary
conserved we excluded the variant to be
pathogenic.
In another SRS patient with 11p15 hypo-
methylation we identified heterozygosity for a
silent substitution in exon 9 (g.16382A>G). Based
on the fact that this variant is silent we concluded
that it is not pathogenic.
Heterozygosity for the new variant in the
3´UTR (g.26945T>C) was detectable in an
idiopathic SRS patient as well as in an 11p15
hypomethylation carrier, therefore a pathogenic
relevance for these etiologically different groups
is not conceivable.
In summary, we did not detect any pathogenic
mutation in the BORIS gene similarily to the,
Bernier- Latmani et al. (2009)  data. Of course we
can not exclude that point mutations or large
genomic imbalances in BORIS might be
responsible for single cases. Although many
Table 1: Description of PCR conditions and primer sequences for analysis of the BORIS gene.
Exon Primer sequence (5’>3’) Annealing temperature/ Size Size of
/Fragment Number of cycles of PCR
exon products
EXON 1 F 5’- ACT ACC CAG TCT TCC AGT GC-3’ Platinum Taq (Invitrogen)  71 bp  604 bp
R 5’- GCC TAG CAA GTT TCA GGT CC-3’ Annealing temperature -57OC
Number of cycles- 35
EXON 2 F 5’- CAT TGT TCT GAC CCT ACT AA-3’ Taq polymerase (Invitrogen)  553 bp  829 bp
R 5’- TGG GAA GTA TTT GTA CTG TC-3’ Annealing temperature -53OC
Number of cycles- 34
EXON 3 F 5’ - GAC AGT ACA AAT ACT TCC CA-3' Taq polymerase (Invitrogen)  210 bp  565 bp
R 5’ - CAA TTA CCA TCA CCT GCC CA-3’ Annealing temperature -55OC
Number of cycles- 34
EXON 4 F 5’- TGG TGT CCT GAA TTG CTT CG-3’ Taq polymerase (Invitrogen)  170 bp  511 bp
R 5’-TAC CAC AGA TGC ATG TGA GA-3’ Annealing temperature -51OC
Number of cycles- 34
EXON 5 F 5’-TCT CAC ATG CAT CTG TGG TA-3’ Taq polymerase (Invitrogen)  133 bp 333 bp
R 5’-TGG AGT AAC TTG TAC AGC AG-3’ Annealing temperature - 51OC
Number of cycles- 34
EXON 6 F 5’-CTC TCA GAA CTG CTG CTC AT-3’ Taq polymerase (Invitrogen)  120 bp  387 bp
R 5’-AAC ACT GTA GGT ACT AGG CC-3’ Annealing temperature - 54OC
Number of cycles- 34
EXON 7 F 5’ - GAC ATA AGC TGT CTG GGC TT-3’ Taq polymerase (Invitrogen)  149 bp  498 bp
R 5’ - ATG AGA TGC AGC CAC CAG AT-3´ Annealing temperature -59OC
Number of cycles- 34
EXON 8 F 5’-GGA AGG AAC TAG CAT GTT CC-3’ Taq polymerase (Invitrogen)  160 bp  424 bp
R 5’-GCT CAC AGT TGC TTT CTG GT-3’ Annealing temperature - 51OC
Number of cycles- 34
EXON 9 F 5’ -GAG TGA ATG CTG CCT TGT TC-3’ Taq polymerase (Invitrogen)  182 bp  409 bp
R 5’ -TGA CAT TGT CCT CCT GAG AT-3’ Annealing temperature - 51OC
Number of cycles- 34
EXON 10 F 5’-TAG CGA GGT GTG TGG AAT TG-3’ Taq polymerase (Invitrogen)  166 bp  426 bp
R 5’-GAC CGA CTG GTG GAC AAA TA-3’ Annealing temperature - 51OC
Number of cycles- 34
EXON 11.1 F 5’-AAC ATG CTT GCT GCC GTG TT-3’ Taq polymerase (Invitrogen)  151 bp  693 bp
R 5’ -TGA CTG TGG AAG CAC TAG CT-3’ Annealing temperature - 57OC
Number of cycles- 34
EXON 11.2 F 5’-GAG GGT AAC ACC TCA AAC CT-3’ Taq polymerase (Invitrogen)  -  434 bp
R 5’-TTT CAT ACC TGC CAA GGA GC-3’ Annealing temperature - 51OC
Number of cycles- 34
EXON 11.3 F 5’-GGT ATA GGA GCA AGG TTC AC-3’ Taq polymerase (Invitrogen)  -  749 bp
R 5’-CTC CAC ATT CTC TCC AGA CA-3’ Annealing temperature - 57OC
Number of cycles- 34
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2
(rs6070128) g.1041G/G 3 4
g.1041C/C 2 3
g.1041G/C 5 3
(rs6025606) g.1422A/A 2 3
g.1422G/G 5 5
g.1422A/G 3 2
5
g.6267G/G 10 9
g.6267G/A - 1
6
(rs6025601) g.9348T/T 9 8
g.9348T/C 1 2
9
(rs6070122) g.16392C/C 9 0
g.16392C/G 1 0
g.16382A/A 10 9
g.16382A/G 0 1
11.2
(rs62204256) g.26874G/G 6 6
g.26874G/A 4 4
g.26945T/T 9 9
g.26945T/C 1 1
Table 2:  Description of genomic variants in our
cohort of Silver-Russell syndrome patients (The
nucleotide numbering is based on clone
gi:51511747; the new variants are printed in bold
face).
Exon Variant Frequency Frequency
in idio in SRS
pathic patients
SRS  with ICR1
hypome-
thylation
studies deliver valuable data about methylation
pattern establishment, alterations and gene
expression regulations our study shows that the
basis of methylation and its influence on the
phenotype still remains unknown in Silver-
Russell syndrome.
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